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INTRODUCTION
When tissues are injured, vasodilation of capillaries and
extravasation of plasma proteins into the interstitial tissue mark
the onset of vascular remodeling following tissue assault (Bhushan
et al., 2002). These processes are crucial not only for initiating a
healing response, but also for enabling re-establishment of tissue
homeostasis. Although molecules that regulate aspects of vascular
stability and/or leakage have been identified, the molecular
mechanisms controlling transport of macromolecules across the
endothelium have only recently begun to be defined. Extravasation
of plasma proteins is subject to regulation by many factors – some
affect vessel leakiness by regulating the formation of openings in
venular endothelium, resulting in exposure of subendothelial
basement membranes to capillary lumens (Feng et al., 1997;
Hashizume et al., 2000; Feng et al., 2002; McDonald and Baluk,
2002), whereas others regulate the diffusion of macromolecules into
interstitium (McKee et al., 2001; Pluen et al., 2001; Brown et al.,
2003). In the resting state, large plasma proteins such as albumin
are transported across the endothelial body through a series of
vesicles that may or may not fuse to form transcellular channels
(Mehta and Malik, 2006), underscoring the fundamental
importance of transcellular pathways in maintaining the semi-
permeable nature of continuous endothelium (Drab et al., 2001).
In contrast to this transcellular-type transport, the majority of
plasma protein leakage in response to inflammatory stimuli occurs
through the formation of gaps between cells, i.e. ‘paracellular’
leakage (Predescu et al., 2002; Mehta and Malik, 2006).
Vascular responses to tissue damage are accompanied by type I
collagen remodeling in perivascular stroma (Page and Schroeder,
1982). The extracellular matrix (ECM), including fibrillar type I
collagen, is rapidly remodeled around blood vessels following the
acute inflammatory processes that accompany tissue damage, as
well as during chronic vascular pathologies, e.g. atherosclerosis,
hypertension, varicosis, restenosis, etc. (Jacob et al., 2001). Matrix
metalloproteinases (MMPs) that cleave interstitial collagens also
play a crucial role in regulating perivascular matrix remodeling.
Indeed, sustained MMP activity is associated with some vascular
pathologies, including atherosclerosis, hypertension restenosis and
aneurysm (Mott and Werb, 2004; Page-McCaw et al., 2007). MMPs
can further contribute to vascular remodeling by liberating
vasoactive cytokines from stromal matrices, including the
angiogenic/permeability factor vascular endothelial growth factor
(VEGF) (Bergers et al., 2000; Sounni et al., 2002), as well as
activating latent growth factors such as transforming growth factor
b (TGFb) (Yu and Stamenkovic, 2000; Mu et al., 2002; Wang et al.,
2006). Despite extensive investigations into the roles of MMPs as
mediators of chronic vascular pathologies, surprisingly little is
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SUMMARY
Innate regulatory networks within organs maintain tissue homeostasis and facilitate rapid responses to damage. We identified a novel pathway
regulating vessel stability in tissues that involves matrix metalloproteinase 14 (MMP14) and transforming growth factor beta 1 (TGFb1). Whereas
plasma proteins rapidly extravasate out of vasculature in wild-type mice following acute damage, short-term treatment of mice in vivo with a broad-
spectrum metalloproteinase inhibitor, neutralizing antibodies to TGFb1, or an activin-like kinase 5 (ALK5) inhibitor significantly enhanced vessel
leakage. By contrast, in a mouse model of age-related dermal fibrosis, where MMP14 activity and TGFb bioavailability are chronically elevated, or
in mice that ectopically express TGFb in the epidermis, cutaneous vessels are resistant to acute leakage. Characteristic responses to tissue damage
are reinstated if the fibrotic mice are pretreated with metalloproteinase inhibitors or TGFb signaling antagonists. Neoplastic tissues, however, are in
a constant state of tissue damage and exhibit altered hemodynamics owing to hyperleaky angiogenic vasculature. In two distinct transgenic mouse
tumor models, inhibition of ALK5 further enhanced vascular leakage into the interstitium and facilitated increased delivery of high molecular weight
compounds into premalignant tissue and tumors. Taken together, these data define a central pathway involving MMP14 and TGFb that mediates
vessel stability and vascular response to tissue injury. Antagonists of this pathway could be therapeutically exploited to improve the delivery of
therapeutics or molecular contrast agents into tissues where chronic damage or neoplastic disease limits their efficient delivery.
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known regarding their role in acute vascular responses, or how they
contribute to vascular homeostasis. Accordingly, we investigated
whether MMPs participate in the early phases of acute tissue repair,
and whether they contribute to the appropriate vascular responses
to tissue damage. In this study, we identified a post-translational
pathway whereby type I collagen fibrils regulate perivascular MMP
activity and TGFb bioavailability, which in turn regulate vascular
homeostasis by altering vessel stability and leakage.
RESULTS
Loss of MMP14 activity increases steady-state vascular leakage
Previous studies have reported that ectopically applied collagenase,
or a reduced accumulation of collagen fibrils in tissue, correlates
with enhanced ‘drug’ delivery to tumors (McKee et al., 2001; Brown
et al., 2003; Loeffler et al., 2006; Gade et al., 2009), thus indicating
that the organization and structure of perivascular collagen fibrils
regulate vascular leakage. To directly assess whether inhibition of
collagenolytic MMP activity impacted vascular leakage, we used
the Miles assay (Miles and Miles, 1952), which is an in vivo assay
of vascular leakage, to analyze the acute cutaneous vascular
response to mustard oil (MO) in mice that were pretreated
systemically with the broad-spectrum metalloproteinase (MP)
inhibitor GM6001. Wild-type (wt) mice were administered with
GM6001 (or vehicle) for 5 days, followed by acute challenge with
MO versus vehicle (mineral oil, MnO) (Inoue et al., 1997), one
minute after receiving an intravenous (i.v.) injection of Evans Blue
(EB) dye, which binds to and marks serum albumin. As expected,
following MO exposure, EB extravasation rapidly increased in ear
tissue interstitium, indicative of plasma protein leakage (Fig. 1A).
Surprisingly, however, prior treatment with GM6001 significantly
increased EB leakage (Fig. 1A). This indicated that the inhibition
of steady-state MP activity rendered vessels more susceptible to
MO-induced acute leakage, and implied a link between steady-state
MP activity and vascular leakage.
To identify the MP associated with this response, we assessed
steady-state and MO-induced EB leakage, using the Miles assay, in
control and homozygous null mice lacking genes that encode
collagenolytic MMPs, i.e. MMP2, MMP8, MMP13 and MMP14 (Fig.
1B,C). Steady-state and MO-induced vascular leakage characteristics
in the ear skin were similar in MMP2, MMP8 and MMP13 null skin
as compared with the skin from littermate control mice (Fig. 1B, and
data not shown). However, in mice lacking MMP14, the steady-state
vascular leakage of EB from ear skin was elevated compared with
aged-matched controls (Fig. 1C), and similar to the leakage following
MO exposure. The steady-state leakage of capillaries in back skin
was also higher in MMP14 null mice versus age-matched
heterozygous and wild-type littermates (Fig. 1D). Thus, the enhanced
leakage of cutaneous vessels in mice lacking MMP14 indicates that
MMP14 participates in regulating steady-state vascular leakage.
Perivascular collagen fibrils increase metalloproteinase activity
and regulate vascular leakage
To further explore how collagen fibril organization and MMP14
activity impacted vascular leakage, we utilized a mouse model of
age-related dermal fibrosis, Cola1(I)r/r mice (Liu et al., 1995), which
exhibit threefold higher tissue collagenolytic activity in skin (Fig.
2A). The Cola1(I)r/r mice also exhibited a ~50% reduction in leakage
following MO exposure (Fig. 2B), which could be rescued fully by
prior treatment of mice with GM6001 (Fig. 2C). Although the levels
of MMP14 protein are similar in wt and Cola1(I)r/r mice (Fig. 2D),
we observed that MMP14 activity, as evidenced by activation of
proMMP2, is markedly enhanced in an ex vivo bioassay using
collagen from Cola1(I)r/r mice (Fig. 2E), and that this enhanced
activity is reflected by constitutive activation of MMP2 in Cola1(I)r/r
mice in vivo (Fig. 2F). To re-affirm that MMP2 was not directly
responsible for the restricted vascular leakage in Cola1(I)r/r) mice,
selective loss of MMP2 in Cola1(I)r/rMMP2–/– mice (Egeblad et
al., 2007) did not alter Cola1(I)r/r susceptibility to MO-induced
capillary leakage (Fig. 2G).
Metalloproteinase-mediated resistance to vascular leakage is
accompanied by decreased appearance of leakage sites in vessels
with perivascular cell coverage
Cola1(I)r/r mice were also found to be resistant to acute vascular
leakage induced by either serotonin or VEGF (Fig. 3A). Moreover,
the resistance to VEGF leakage in Cola1(I)r/r mice was not linked
to changes in the expression or activation of VEGF receptor 2
(VEGFR2) (Fig. 3B), and together suggest that the elevated
collagenolytic activity in Cola1(I)r/r mice reduces the acute vascular
leakage induced by a variety of stimulants.
To further evaluate the pathologic basis underlying reduced
vascular leakage in Cola1(I)r/r mice, we assessed the organization,
architecture and diameter of cutaneous capillary networks in ears
from Cola1(I)r/r mice and their control littermates following MO
exposure. We assessed capillary beds by fluorescent angiography
dmm.biologists.org2
TGFb regulates vascular stabilityRESEARCH ARTICLE
Fig. 1. MMP14 regulates vascular stability. (A) Quantitative assessment of
Evans Blue (EB) dye leakage into interstitial tissue from the ears of control and
GM6001-treated mice (four mice/experimental group) that were ectopically
exposed to either mineral oil (MnO; white bars) or mustard oil (MO; black bars).
Data reflect mean ± standard error of the mean (S.E.M.). *P<0.01.
(B) Quantitative assessment of EB leakage into interstitial tissue from the ears
of MMP2, MMP8 or MMP13 homozygous null (–/–) mice versus respective
control (+/+) mice (four mice/group) treated with mineral oil or mustard oil.
Data reflect mean ± S.E.M. *P<0.01. (C) Quantitative assessment of EB leakage
into interstitial tissue from the ears of MMP14 homozygous null (–/–) mice
versus aged-matched control wild-type or heterozygous (+/+ or +/–) mice
(four mice/group) treated with mineral oil or mustard oil. Data reflect mean ±
S.E.M. *P<0.01. (D) Quantitative assessment of EB leakage into the interstitial
tissue of dorsal skin in untreated age-matched wild-type (+/+), MMP14+/– or
MMP14–/– mice (four mice/experimental group). Data reflect mean ± S.E.M.
*P<0.01.
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using fluorescein-labeled Lycopersicon esculentum (tomato) lectin
that specifically binds to the luminal surfaces of vascular
endothelium (Thurston et al., 1996). The organization and diameter
of capillaries in quiescent vascular beds of control and Cola1(I)r/r
mice were similar, both qualitatively (Fig. 3C) and quantitatively
(Fig. 3D). However, following MO treatment, the total vessel area,
Disease Models & Mechanisms 3
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Fig. 2. Increased MMP14 activity is associated with restricted vascular leakage. (A) Total MP activity (relative fluorescence units, RFU) in ear tissue lysates
from Cola1(I)+/+ and Cola1(I)r/r mice (four mice/experimental group), as assessed by a fluorogenic solution assay utilizing quenched DQ-gelatin. Incubation of
lysates with 1,10-phenanthroline (+; 4.0 mM) eliminated cleavage of the fluorogenic substrate. Data reflect mean ± S.E.M. *P <0.01. (B) Upper panels document EB
dye leakage (blue staining) in the ears of Cola1(I)+/+ (left) and Cola1(I)r/r (right) mice following application of mineral oil (MnO; left ear) or mustard oil (MO; right
ear). The lower panel shows a quantitative assessment of EB leakage into interstitial tissue from Cola1(I)+/+ and Cola1(I)r/r mice (five mice per experimental
group) treated with mineral oil (white bars) and mustard oil (black bars). Data reflect mean ± S.E.M. *P=0.0001. (C) Treatment of Cola1(I)+/+ and Cola1(I)r/r mice
(five mice/experimental group) for 5 days with GM6001 versus vehicle (V) renders Cola1(I)+/+ mice hypersensitive to the vascular leakage induced by mustard oil
(black bars), as compared with mineral oil (white bars), and restores the acute vascular responses in Cola1(I)r/r mice to wt levels. Data reflect mean ± S.E.M.
*P<0.02. (D) Western blot of immunoprecipitated MMP14 protein from the skin of wild-type (+/+) and Cola1(I)r/r (r/r) mice. Upper panel shows MMP14
immunoprecipitated and blotted with antibodies against the catalytic (cat/cat) domain, and the lower panel shows MMP14 recovered and probed with
antibodies against the hemopexin (hp/hp) domain. The left lane (‘c’) is a control lane, which lacked tissue lysates throughout the procedure. Molecular mass
standards in kDa are shown to the left of the blot. (E) Gelatin zymography, representing MDA-MB-231 cells that were stably transfected with vector or full-length
human MMP14 cDNA, grown in gels comprised of collagen that was purified from either Cola1(I)+/+ (+/+) or Cola1(I)r/r (r/r) mice. The cells were assessed for their
ability to activate proMMP2 in either the gel (G) or supernatant (S) fractions. Cleared regions of gel indicating the presence of proMMP2 or MMP2 are shown.
(F) Gelatin substrate zymography of tissue lysates from Cola1(I)+/+ and Cola1(I)r/r mouse ears, topically treated with MnO or MO. The presence of cleared regions
in the gel (white areas) representing proMMP9, proMMP2 and MMP2 are indicated, where each lane reflects lysates from one mouse. (G) Quantitative assessment
of EB leakage in the ear skin of wild-type Cola1(I)+/+, MMP2–/–, Cola1(I)r/r and Cola1(I)r/r/MMP2–/– mice (four mice/experimental group) in response to mustard oil
(black bars), as compared with mineral oil (white bars). Data reflect mean ± S.E.M. *P<0.005.
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and in particular the vessel diameter, increased significantly in
control mice but remained unchanged in the skin of Cola1(I)r/r
mice (Fig. 3C,D).
Since mural cell coverage of blood vessels contributes to
vasodilation and extravasation of plasma proteins, we examined
the presence of perivascular cells on venules in the skin from wt
and Cola1(I)r/r mice by whole-mount immunodetection of a-
smooth muscle actin (aSMA), a marker for mature perivascular
cells (Verbeek et al., 1994). Interestingly, the position and
morphology of aSMA-positive perivascular cells in vehicle-treated
control versus MO-treated Cola1(I)r/r skin were indistinguishable
(Fig. 3E, panels a-c).
Extravasation of plasma proteins into tissue interstitia is also
regulated by the frequency of openings in venular endothelium
(McDonald and Baluk, 2002); accordingly, we injected control and
Cola1(I)r/r mice with fluorescein-labeled Lycopersicon esculentum
lectin (to visualize vasculature), in combination with rhodamine-
labeled Ricinus communis agglutinin I (to visualize luminal
openings). Following MO exposure, numerous leakage sites
appeared in capillary beds of tissue from control mice (Fig. 3E, panel
e), specifically in capillaries where perivascular cell coverage was
prominent (Fig. 3E, panel b). However, the leakage sites were less
abundant in MO-treated Cola1(I)r/r capillaries (Fig. 3E, panel f),
indicating that the enhanced stability of vessels in Cola1(I)r/r mice
correlated with reduced vasodilation following MO challenge and
a diminished frequency of venular openings, independent of similar
perivascular cell coverage.
MMP14 regulates TGFb bioactivity and vascular stability
In addition to activating proMMP2, MMP14 also regulates the
bioavailability of several chemokines and growth factors, most
notably latent TGFb (Werb, 1997; Mu et al., 2002; Alfranca et al.,
dmm.biologists.org4
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Fig. 3. Morphological assessment of vascular resistance to
mustard oil. (A) Quantitation of EB leakage into interstitial
stroma following intradermal (i.d.) injection of VEGF120, VEGF164
or serotonin in Cola1(I)+/+ (grey bars) and Cola1(I)r/r (black bars)
mice. *P<0.05 (two-tailed Mann-Whitney test) comparing
Cola1(I)+/+ mice with Cola1(I)r/r mice for the respective
compounds at increasing doses. (B) Western blot analysis of
phosphoVEGFR2 protein from tissue lysates (back skin)
harvested from Cola1(I)+/+ (+/+) or Cola1(I)r/r (r/r) mice (four
mice/experimental group) following i.d. injection of VEGF164
and immunoprecipitation with antibodies against VEGFR2. The
lower panel shows the total VEGFR2 recovered from wt (+/+) or
Cola1(I)r/r (r/r) mice. Blots were stripped and reprobed with
antibodies against phosphotyrosine (PY20), shown in the upper
panel. P, PBS; V, VEGF164. (C) Fluorescent angiography of whole-
mounted ears following fluorescein-labeled Lycopersicon
esculentum lectin perfusion (green staining) of Cola1(I)+/+
(panels a,b) and Cola1(I)r/r (panels c,d) mice treated with either
mineral oil (MnO) or mustard oil (MO). Bar, 200mm. (D) The
upper graph shows a quantitative assessment of vascular area
in the ears of Cola1(I)+/+ (+/+) versus Cola1(I)r/r (r/r) mice (five
mice/experimental group, S.E.M.) following mineral oil (white
bars) or mustard oil (black bars) treatment. *P=0.0357. The
lower graph shows a quantitative assessment of micro (<5mm)
and macro (>5mm) vessel diameters in Cola1(I)+/+ (+/+) and
Cola1(I)r/r (r/r) ear skin (five mice/experimental group) following
mineral oil (white bars) and mustard oil (black bars) treatment.
Data reflect mean ± S.E.M. *P=0.0001. (E) Representative
confocal images showing the perivascular cell phenotype and
sites of vascular leakage. Panels a-c: immunohistochemical
detection of aSMA-positive perivascular cells (red staining) in
whole-mounted ears from Cola1(I)+/+ (panels a,b) and
Cola1(I)r/r (panel c) mice following mineral oil (panel a) or
mustard oil (panels b,c) stimulation and intravenous (i.v.)
injection of fluorescein-labeled Ricinus communis agglutinin I
(green staining, arrowheads). Panels d-f: representative
pseudocolored confocal images showing ears from Cola1(I)+/+
(panels d,e) and Cola1(I)r/r (panel f) mice, where ears were
treated with mineral oil (panel d) or mustard oil (panels e,f),
followed by fluorescent angiography with fluorescein-labeled
Lycopersicon esculentum lectin perfusion (pink staining; panels
d-f) and rhodamine-labeled Ricinus communis agglutinin I (blue
staining, arrowheads, panels e,f). The blue staining in panel a
reflects DAPI staining of nuclei in the ear tissue. Bars, 200mm (E,
panels a-c); 100mm (E, panels d-f).
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2008), which can profoundly impact vascular integrity. Given that
MMP2 deficiency failed to alter vascular stability alone (Fig. 1B),
or in combination with the Cola1(I)r/r mutation (Fig. 2G), we
evaluated whether TGFb1 might mediate a MMP14- or collagen-
regulated vascular response. We assessed whole-skin lysates by
ELISA and found decreased levels of total TGFb1 in hyperleaky
MMP14-deficient mice (Fig. 4A). We also found, in leakage-
resistant Cola1(I)r/r mice, an elevated level of total TGFb1 that was
independent of MMP2 (Fig. 4B and supplementary material Fig.
S1A). Moreover, although Tgfb1 mRNA expression (Fig. 4C) and
the synthesis of latent TGFb [the TGFb latency-associated peptide
(LAP)] (Fig. 4D) were similar in both wild-type and Cola1(I)r/r mice,
we observed an increase in the mature, bioactive form of TGFb1
in Cola1(I)r/r tissue lysates (Fig. 4E,F), which was sensitive to
GM6001 inhibition (Fig. 4G). Using an organotypic cell-based assay
with cells that constitutively express MMP14, which were cultured
on collagen derived from Cola1(I)r/r mice, we confirmed that the
enhanced bioavailability of TGFb1 (and MMP2 activity) was indeed
regulated directly by MMP14, and enhanced in the presence of
mutant collagen fibrils (Fig. 4H and supplementary material Fig.
S1B).
To directly demonstrate the role of TGFb in regulating vascular
stability and response, we administered a pan-TGFb-neutralizing
antibody, which neutralizes the bioactivity of all TGFb isoforms in
vivo (Yamamoto et al., 1999; Neptune et al., 2003), to 6-week-old
control and Cola1(I)r/r mice prior to MO challenge. Similar to our
results following the administration of GM6001 (Fig. 2C),
neutralization of TGFb in Cola1(I)r/r mice following MO
stimulation resulted in appropriate acute vascular remodeling and
reinstated the characteristic EB leakage to a level comparable to
untreated controls (Fig. 4I).
The TGFb type I receptor ALK5 (activin-like kinase 5) is
expressed in both CD31+ endothelial cells and aSMA-positive
perivascular cells (data not shown). Similar to treatment with the
pan-TGFb-neutralizing antibody, responsiveness to MO-induced
vascular leakage was restored following administration of an
inhibitor of ALK5 (ALK5-I) (Fig. 4J); it also significantly enhanced
the steady-state vascular leakage in unstimulated skin (Fig. 4K).
Thus, consistent with the hyperleaky phenotype of MMP14 null
mice, which have decreased steady-state levels of TGFb, vessel
stability and vascular leakage in Cola1(I)r/r mice are susceptible to
regulation by modulation of metalloproteinase activity, TGFb
bioavailability and signaling downstream of ALK5.
Ectopic expression of TGFb reduces acute vascular leakage
We reasoned that if neutralization of TGFb or blockade of ALK5
signaling enhanced steady-state and acute leakiness, then sustained,
ectopic expression of TGFb1 would phenocopy the elevated
MMP14 activity that we observed in Cola1(I)r/r mice, and result
in resistance to leakage. To test this hypothesis, we utilized an
inducible TGFb1 bigenic mouse model (Cao et al., 2002) that
expresses TGFb1 in basal keratinocytes of skin following induction
by RU486 (Lu et al., 2004). Because exposure to RU486 for 6 days
induced a psoriatic phenotype (Fig. 5A, panels a,b), we performed
the EB leakage assay after 3 days of exposure to RU486, prior to
the onset of psoriasis, when the skin of the bigenic mice appeared
‘normal’ (Fig. 5A, panel a) even though RU486-induced expression
of TGFb1 was prominent in keratinocytes (Fig. 5A, panel c).
Significantly, the bigenic mice treated with RU486 for 3 days were
resistant to MO-induced EB leakage (Fig. 5B), confirming that
sustained ectopic expression of TGFb phenocopied the vascular
effects linked to elevated MMP14 activity in Cola1(I)r/r mice.
TGFb attenuates vascular leakage in aged and neoplastic tissue
The data above indicate that MMP14-activated TGFb1 regulates
vascular homeostasis and the vascular response to acute tissue
damage via signaling through ALK5. To determine whether this
signaling pathway was susceptible to regulation in aged tissues
where fibrosis and the cross-linking of collagen fibrils can
compromise tissue hemodynamics, we utilized aged C57BL/6
mice. Similar to young animals, transient blockade of ALK5 in aged
mice led to enhanced vessel leakiness following MO stimulation
(Fig. 6A).
To determine whether the ALK5 signaling pathway was also
active in chronically leaky angiogenic vessels, such as those found
in neoplastic tissues, we utilized two transgenic models of epithelial
carcinogenesis (Guy et al., 1992; Coussens et al., 1996). Angiogenic
blood vessels in the premalignant skin of K14-HPV16 transgenic
mice exhibit increased steady-state leakiness (Eichten et al., 2007)
in capillaries that are largely devoid of aSMA-positive perivascular
cells (Fig. 6B,C). Transient ALK5 blockade in K14-HPV16
transgenic mice further increased vessel leakage and extravasation
of EB dye (Fig. 6C). Together, these data indicate that the ALK5
signaling pathway remains susceptible to therapeutic modulation
in both aged and angiogenic vessels.
Based on this, we hypothesized that antagonizing ALK5-
mediated signaling in tumor vessels would enhance leakage and
potentially improve the delivery of high molecular weight
compounds, such as antibodies, liposomes or contrast agents, into
the tumor interstitium. Moreover, to ensure that inhibition of TGFb
was influencing vascular permeability and not simply modulating
bulk flow, we performed live imaging of mice to dynamically follow
the leakage of high and low molecular weight dextrans into
mammary carcinomas in MMTV-PyMT transgenic mice (Guy et
al., 1992). ALK5 inhibition conferred a significant increase in the
leakage of 70 kDa dextran into late-stage carcinomas (Fig. 6D,E).
Moreover, although ALK5 blockade had no effect on the initial
leakage of 10 kDa dextran, it significantly increased the retention
of dextran in the tumor. Thus, transient blockade of ALK5 in live
mice bearing large invasive tumors enhanced the leakiness of
angiogenic vessels, enabling increased delivery of high molecular
weight compounds and increased retention of low molecular
weight compounds to tumor tissue. Together, these data indicate
that TGFb-mediated signaling through the ALK5 receptor in
vascular cells regulates vascular stability and leakage in homeostatic,
acutely damaged, aged, and angiogenic tissue, and thus reveals a
therapeutic opportunity to enhance the delivery of drugs to tissue
where hemodynamics limit that possibility.
DISCUSSION
Herein we describe a novel mechanism by which TGFb regulates
vessel stability and leakage in homeostatic, acutely damaged and
angiogenic blood vessels. Our findings demonstrate that, in
cutaneous vasculature, steady-state levels of MMP14 and TGFb
regulate homeostatic vascular leakage via ALK5 signaling, and that,
together, they regulate extravasation of plasma proteins into the
Disease Models & Mechanisms 5
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Fig. 4. MMP14-activated TGFb restricts the vascular response. (A) ELISA of ear tissue lysates from control (MMP14+/–) or MMP14 null (–/–) mice (three
mice/experimental group), showing the reduced levels of total TGFb1 in the skin of MMP14 null mice. Data reflect mean ± S.E.M. *P=0.0001. (B) Total TGFb1
present in tissue lysates from wild-type (+/+/+/+), Cola1(I)r/r (r/r/+/+), MMP2–/– (+/+/–/–) and Cola1(I)r/r/MMP2–/– (r/r/–/–) ear skin (five mice/experimental group)
measured by ELISA. Data reflect mean ± S.E.M. *P<0.01. (C) TGFb1 mRNA in the ear skin from Cola1(I)+/+ (+/+) and Cola1(I)r/r (r/r) mice, as assessed by northern
blot analysis. The 18S RNA is shown as a control. (D) Western blot analysis of Cola1(I)+/+ (+/+) and Cola1(I)r/r (r/r) ear tissue lysates under reducing conditions
using an antibody to LAP. The ~75 kDa reactive band, corresponding to monomeric LAP, was identified by comparing it with a-tubulin (loading control).
Molecular mass standards are given in kDa on the left. (E) Western blot analysis of immunoprecipitated proteins reveals the presence of an ~25 kDa reactive
band, correlating to the mature bioavailable form of dimeric TGFb1, in ear tissue lysates from Cola1(I)r/r (r/r) mice that is not detectable in tissue lysates from
Cola1(I)+/+ (+/+) mice. The lane labeled ‘c’ shows immune complexes in the buffer control (no tissue lysate). The presence of murine heavy (H) and light (L)
immunoglobulin chains is also shown. (F) TGFb1 bioavailability as assessed by PAI-1 luciferase reporter activity following incubation of MLE-PAI-1 cells with ear
tissue lysates from Cola1(I)+/+ or Cola1(I)r/r mice (lysates from four mice/experimental group, repeated in triplicate). Samples were incubated with anti-IgG
control antibodies (aIgG) or pan-neutralizing antibodies against TGFb (aTGFb). Data reflect mean ± S.E.M. *P=0.01. (G) The presence of a low molecular weight
~25 kDa reactive band, correlating to the mature bioavailable form of dimeric TGFb1, in ear tissue lysates from Cola1(I)+/+ and Cola1(I)r/r mice is reduced by prior
in vivo treatment of mice with GM6001(GM). The lane labeled ‘c’ shows immune complexes in the buffer control (no tissue lysate). The presence of murine heavy
(H) and light (L) immunoglobulin chains is also shown. Molecular mass standards are given in kDa on the left. (H) Endogenous TGFb1 bioavailability assessed by
the PAI-1 luciferase reporter activity of MLE-PAI-1 cells, following incubation with supernatants harvested from MDA-MB-231 cells that were stably transfected
with either vector or human MMP14 and grown in gels comprised of collagen purified from Cola1(I)+/+ (+/+) or Cola1(I)r/r (r/r) mice. Supernatants were also
treated with GM6001 or a pan-neutralizing antibody against TGFb. Each data point reflects the mean ± S.E.M. from the supernatants of four wells, pooled and
repeated in triplicate. *P<0.01. (I) Upper panels show EB leakage in the ears of Cola1(I)+/+ (left two panels) and Cola1(I)r/r (right two panels) mice that were
treated with non-specific immunoglobulin or neutralizing antibodies to all TGFb isoforms, followed by topical exposure to mineral oil (left ear) or mustard oil
(MO; right ear), with quantitation of leakage assessed using the Miles assay (five mice/experimental group). Data reflect mean ± S.E.M. *P<0.05. (J) Quantitative
assessment of EB leakage in the interstitial ear tissue of Cola1(I)+/+ and Cola1(I)r/r mice that were treated with mineral oil (MnO; white bars) and mustard oil (MO;
black bars); the assessment was carried out after a 5-day pretreatment with vehicle (V) or an inhibitor to ALK-5 (A5-I). Each bar reflects five mice/experimental
group and the data indicate mean ± S.E.M. *P<0.03. (K) Quantitative assessment of EB leakage in steady-state (unstimulated) Cola1(I)+/+ and Cola1(I)r/r mice (back
skin), assessed after treatment with vehicle (v) or ALK5 inhibitor (ALK5-I) for 5 days (four mice/experimental group). Data reflect mean ± S.E.M. *P<0.02.
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tissue interstitium. Moreover, we provide further evidence that a
post-translational pathway, mediated by perivascular type I collagen
and MMP14 activity, controls the bioavailability of TGFb. Taken
together, these data indicate a central role for stromal
metalloproteinase-activated TGFb in mediating vascular
homeostasis and remodeling, and further indicate that TGFb
and/or MMP14-selective antagonists may enhance vascular leakage
and the delivery of therapeutics to tissues where hemodynamics
limit efficient drug delivery (Fig. 7).
TGFb regulates vascular homeostasis and the response to tissue
damage
TGFb has long been implicated as a regulator of vascular integrity
(Pepper, 1997; Gleizes and Rifkin, 1999; Tuxhorn et al., 2002);
vasculogenic and angiogenic processes (Dickson et al., 1995;
Pepper, 1997); and endothelial and perivascular cell proliferation
and/or differentiation (Sato, 1995; Yan and Sage, 1998; Vinals and
Pouyssegur, 2001). Vascular abnormalities have also been
described in TGFb null mice, as well as in mice lacking various
TGFb type I and II receptors (Dickson et al., 1995; Seki et al.,
2003; Seki et al., 2006). Despite extensive research on the impact
of TGFb on vasculature, the mechanisms by which TGFb regulates
vascular development and function are complex and remain
controversial.
TGFb differentially impacts endothelial and vascular smooth
muscle cells in a concentration-, substrate- and tissue-specific
context (Madri et al., 1992; Yan and Sage, 1998). For example, in
bleomycin-induced pulmonary edema, TGFb promotes vascular
leakage by acting directly on pulmonary endothelial cells in concert
with integrin a5b1 (Pittet et al., 2001; Su et al., 2007). TGFb also
induces the expression of angiopoietin-like protein 4 (Angpt-4) that,
in turn, disrupts endothelial cell junctions, increases leakage, and
promotes tumor cell emigration and metastasis to the lungs (Padua
et al., 2008).
By contrast, in pancreatic tumors, vascular leakage is induced
when TGFb type I receptors are inhibited, accompanied by
decreased Smad2-regulated signaling cascades, specifically in
endothelia (Kano et al., 2007). In the brain, the inhibition of TGFb
type I ALK5 receptors also increases leakage (of the blood brain
barrier), accompanied by changes in the expression of tight junction
adhesion proteins (Ronaldson et al., 2009).
Our data indicate that, in cutaneous and mammary vessels,
TGFb acts primarily through the ALK5 receptor to restrict vessel
leakage. Indeed, our localization data showing ALK5 expression in
perivascular support cells (data not shown) concur with recent in
vivo studies showing that the deletion of ALK5 in mice results in
the loss of mural cells, whereas vessel lumens remain intact (Seki
et al., 2006). Although we cannot rule out the possibility that TGFb
may also directly or indirectly influence the endothelial component
of the vascular wall in vivo (Cambier et al., 2005; Roviezzo et al.,
2005; Parikh et al., 2006), recent studies with targeted, endothelial
cell-selective deletion of ALK5 reveal normal vascular development
and morphology, supporting previous observations that ALK5 is
more crucial for smooth muscle rather than endothelial cell
function (Park et al., 2008). Moreover, despite the fact that either
MMP14 (Lehti et al., 2005) or TGFb can promote vessel investment
by perivascular cells, and that TGFb alters the accumulation of
macromolecules in pancreatic tumors treated with TGFb inhibitors
and has been linked to reduced pericyte coverage (Hirschi et al.,
1998; Kano et al., 2007), we did not observe any differences in
perivascular cell coverage in Cola1(I)r/r tissues, indicating that
TGFb may activate multiple pathways in perivascular cells leading
to stabilization of vasculature.
In vascular smooth muscle cells, TGFb can bind to ALK5 and
activate Smad2 and Smad3 to promote differentiation, and increase
contractility and ECM synthesis (Dumont and Arteaga, 2003).
Although studies in cultured endothelial cells also described ALK5-
mediated increases in Smad3 through an MMP14-dependent
activation of TGFb (Alfranca et al., 2008), we did not observe any
changes in vascular leakage in Smad3-deficient mice (N.E.S. and
L.M.C., unpublished observations), indicating that ALK5-mediated
changes in vascular leakage in vivo probably impact the Smad2
pathway in smooth muscle cells.
Importantly, several studies have found that ALK5 inhibition
effectively reduces matrix synthesis and impairs fibrotic reactions in
organs including the skin (scleroderma) and kidney (Ishida et al.,
2006). Moreover, TGFb-induced fibroblast or smooth muscle cell
contractility can increase the tension on extracellular matrices
leading to increased interstitial fluid pressure, which further restricts
capillary outflow (Heldin et al., 2004), whereas ALK5 inhibition
reduces dermal fibroblast activation in vivo (Ishida et al., 2006). In
tumors, drug delivery is influenced considerably by the increased
interstitial fluid pressure caused by the increased permeability of
tumor vasculature and the absence of functional lymphatics
(Minchinton and Tannock, 2006), and is exacerbated further by
increased collagen deposition and fibrosis in activated tumor stroma
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Fig. 5. TGFb regulates steady-state and acute vascular leakage.
(A) Images of ears from bigenic K14-GLp65/tata.TGFb1 mice treated
with RU486 on the ear skin for 3 days (a) or 6 days (b). Although ears
exhibited psoriasis after 6 days of RU486-induced TGFb1 expression,
ears appeared normal at 3 days. Lower panels show prominent TGFb1
immunoreactivity (*) in the ear skin of mice treated for 3 days with
RU486 (c), but not for sesame oil (SO)-treated control mice (d). Bar, 50
mm (c,d). (B) Upper panels show the appearance of extravasated EB
dye (blue staining) in the ears of bigenic K14-GLp65/tata.TGFb1 mice
treated with mineral oil (MnO) or mustard oil (MO) after 3 days of
pretreatment with sesame oil (SO) or RU486. The lower panel shows
the corresponding quantitative analysis of EB dye leakage for each
experimental condition (five mice/experimental group), as
determined by the Miles assay. Data reflect mean ± S.E.M. *P<0.01.
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(Heldin et al., 2004). Reduced type I collagen accumulation enhances
drug penetration and drug responses (McKee et al., 2001; Brown et
al., 2003; Loeffler et al., 2006; McKee et al., 2006), as does ectopic
delivery of interstitial collagenases (Gade et al., 2009). Thus, transient
blockade of TGFb would be expected to not only reduce matrix
synthesis, but also to reduce perivascular and stromal cell
contractility, leading to reduced interstitial fluid pressure, and
improved tissue perfusion and drug delivery.
Indeed, in the MMTV-PyMT transgenic mouse model of
mammary carcinogenesis, ALK5 inhibition increased the leakage
of high molecular weight dextran into tumor tissue, and increased
the retention of low molecular weight dextran in late-stage tumors,
indicating that TGFb and ALK5 regulate vascular paracellular
transport mechanisms responsible for the transport of high
molecular weight molecules. Although tissue specificity may dictate
which intracellular signaling pathway regulates the TGFb effects
on vascular homeostasis, it is clear that multiple tissues, in addition
to skin and mammary tissue, respond similarly to TGFb blockade.
In thyroid tumors, inhibition of the TGFb type II receptor
(TGFbRII) leads to reduced interstitial fluid pressure and outward
flow of serum proteins from capillaries (Lammerts et al., 2002),
and in pancreatic tumors, this leads to the increased accumulation
of macromolecules in stroma (Kano et al., 2007).
In Cola1(I)r/r mice, where steady-state levels of bioavailable
TGFb are maintained at elevated levels, we observed a reduction
in luminal openings in vessels with a diameter greater than 5 mm.
However, in both Cola1(I)r/r mice and aged wild-type mice that
accumulate non-enzymatically cross-linked collagen and exhibit
vascular dysfunction (Susic, 2007), inhibiting signaling by the
ALK5 receptor restores the appropriate vascular response. Thus,
the ability of TGFb to impact matrix synthesis and organization,
as well as the contractility of perivascular cells, and to reduce
vascular openings, may collectively contribute to restricted vascular
leakage in Cola1(I)r/r mice.
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Fig. 6. Inhibition of ALK5 increases vascular leakage
in neoplastic tissue. (A) Quantitative assessment of EB
leakage in the interstitial ear tissue of 1-, 12- and 18-
month-old wild-type C57BL/6 mice treated with mineral
oil (MnO; white bars) and mustard oil (MO; black bars),
assessed after 5 days of pretreatment with vehicle
(DMSO) or an inhibitor to ALK-5 (ALK5-I). Each bar reflects
mean ± S.E.M., with five mice per 1- and 12-month-old
experimental groups, and four mice for the 18-month-old
group. *P<0.03. (B) Representative confocal images
showing perivascular cell coverage and vascular leakage
sites in blood vessels of premalignant angiogenic skin
from a K14-HPV16 transgenic mouse (Eichten et al.,
2005). On the left, aSMA-positive perivascular cells (red
staining, red arrowheads) and blood vessels (green
arrowheads) are revealed, showing that the smaller
capillary networks lack aSMA-positive perivascular cell
coverage. On the right, sites of vascular leakage are
revealed by fluorescein-labeled Ricinus communis
agglutinin I binding (green staining, green arrowheads)
in capillaries that are also not covered by aSMA-positive
perivascular cells (red staining, red arrowheads). Bar, 100
mm. (C) Quantitative assessment of EB leakage in age-
matched 4-month-old, wild-type negative littermate
[(–)LM] mice or K14-HPV16 transgenic mice (five
mice/experimental group) with premalignant dysplastic
skin lesions that were either untreated (0/), or treated with
vehicle (V) versus ALK-5 inhibitor (ALK5-I). *P<0.01. (D)
Leakage of 70 kDa (green) and 10 kDa (red) dextrans into
mammary adenocarcinomas in MMTV-PyMT mice treated
with ALK5 inhibitor (ALK-I) or vehicle (DMSO). Dextrans
were injected intravenously, together with non-targeted
quantum dots (blue) that were used to differentiate
between intravascular and extravascular spaces. Images
are shown at the indicated times after i.v. injection, with
false-coloring of the pixels that are positive for the
respective dextrans. Bar, 100mm. (E) Quantitative
assessment of dextran leakage in mammary tumors from
95-day-old MMTV-PyMT mice at the indicated times after
i.v. injection of the fluorescent dextrans (five
mice/experimental group, error bars reflect S.E.M.).
*P<0.05.
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Stromal regulation of MP activity and TGFb bioavailability
Our data indicate the existence of a novel feed-forward mechanism
by which type I collagen fibrils regulate the activity of MMP14 and
the bioavailability of TGFb. Previous studies have reported that type
I collagen upregulates MMP14 mRNA expression (Haas et al.,
1999), and increases cell surface stabilization of the MMP14
protein (Haas et al., 1999), consistent with our data (supplementary
material Fig. S1B). Moreover, collagen interactions with the MMP14
hemopexin C domain enhance the formation of multimeric
MMP14 complexes, which, in turn, activate proMMP2 (Tam et al.,
2002). Typically, MMP14 protein is degraded autolytically following
MMP2 activation, and subsequent degradation of collagen further
downregulates MMP14 mRNA expression, whereas addition of
metalloproteinase inhibitors leads to prolonged stabilization of
MMP14 on the cell surface in cell-based assays (Bernardo and
Fridman, 2003). Thus, in Cola1(I)r/r mice, the inability to cleave
collagen probably results in surface clustering of MMP14, and
stabilized MMP14 enables localized cleavage of the TGFb LAP to
liberate active TGFb, as well as the enhanced presence of the active
form of MMP2.
LAP-TGFb1 can localize to cell surfaces via integrins (avb1, avb6
and avb5) (Annes et al., 2003) to facilitate TGFb activation
(Cambier et al., 2005). In airway epithelia, LAP-TGFb also binds
to avb8, and cleavage of LAP from the TGFb-avb8 complex is
mediated by MMP14 (Mu et al., 2002; Araya et al., 2006). As avb8
is not expressed by vascular smooth muscle cells (Mu et al., 2002),
stabilized collagen fibrils in Cola1(I)r/r mice may directly activate
and stabilize MMP14, which then subsequently activates latent
TGFb. Moreover, although MMP2 can also induce maturation of
TGFb1 or degrade fibrillin, a microfibril-anchoring protein whose
loss is linked to activation of TGFb (Dallas et al., 2002; Mu et al.,
2002; Annes et al., 2003), our data demonstrate that MMP14 null
mice, but not MMP2 null mice, display vascular phenotypes similar
to TGFb inhibition. Evaluation of steady-state and MO-induced
vascular leakage in MMP2-deficient Cola1(I)r/r mice was similar
to that found in Cola1(I)r/r mice. Thus, by interfering with the
dynamic interplay between collagen, MMP14 and TGFb, we have
identified a novel post-translational pathway that regulates vascular
homeostasis.
Summary and perspectives
Findings from this study support several important new concepts
(Fig. 7). First, steady-state levels of TGFb in cutaneous tissue restrict
vascular leakage and confer vascular stability. Second, ECM
proteins that provide structural integrity also play crucial roles in
regulating TGFb activation, as well as MMP activity (Tam et al.,
2002). In a fibrillar state, pericellular type I collagen regulates the
expression and activity of the collagenolytic proteases that degrade
it (i.e. MMP14 and MMP2) (Overall, 2001), as well as the
bioavailability of TGFb, to directly regulate cell and tissue status.
Thus, fibrillar collagen represents an abundant sensor-type
molecule endowed with an inherent self-regulating ‘switch’ that is
engaged upon rapid collagen degradation following acute trauma
and that, in turn, suppresses a post-translational pathway
maintaining vascular stability. Third, these data provide a novel link
between type I collagen, MMP14 and TGFb activation and the
regulation of vasodilation and extravasation of plasma proteins –
perturbations of which manifest in the pathogenesis of several
cutaneous diseases. The present study demonstrates that, in
microenvironments where type I collagen fibrils remain stable
following acute tissue stimulation, sustained steady-state
metalloproteinase activity and TGFb bioavailability exert dominant
control over vascular cells and limit their ability to mount an acute
response. Together, these observations support the hypothesis that
antagonizing MMP14 or TGFb activity could repress vascular
quiescence in fibrotic tissues, increase plasma protein extravasation
in hyperactive tissues, and normalize infiltrating responses to
resolve fibrotic disorders, whereas enhanced MMP or TGFb activity
may encourage vascular quiescence. Clinically, these data imply that
pharmacologic agents that modulate type I collagen fibril status,
MMP14 activity and/or TGFb bioavailability, and/or downstream
ALK5 signaling, could profoundly alter tissue hemodynamics that
could be therapeutically exploited to improve drug delivery or
molecular imaging.
METHODS
Animal husbandry
All mice were maintained within the UCSF Laboratory for Animal
Care barrier facility, and all experiments involving animals were
approved by the Institutional Animal Care and Use Committee
(IACUC) of UCSF. Cola1(I)r/r mice were derived from the colony
at Massachusetts General Hospital, Boston, where the mutation
was targeted to the J1/129 embryonic stem cells and introduced
into the C57BL/6 strain, as described previously (Liu et al., 1995).
Backcrosses to FVB/n (N5) mice were performed to create an
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Fig. 7. A model for MMP14- and TGFb-mediated regulation of vascular
homeostasis and leakage during vascular remodeling. The major
components of mature capillary networks include endothelial cells, vascular
smooth muscle cells and the extracellular matrix. Under homeostatic
conditions, these networks are maintained in quiescent states. Following
physiologic or pathologic stimulation involving matrix remodeling and/or the
increased presence of vascular mediators [VEGF, serotonin, mustard oil (MO)],
innate programs are rapidly activated that foster vascular remodeling
accompanied by increased leakage of plasma proteins into the tissue
interstitium. Increased steady-state levels of MMP14 and/or TGFb1 lead to the
enhanced stability of blood vessels that resist acute leakage following
stimulation. By contrast, reducing the steady-state activity of MMP14 or the
levels of bioavailable TGFb, or treatment with ALK5/TGFb receptor inhibitors,
relieves vessel stability rendering homeostatic vessels leaky, and enhances
leakage in blood vessels that are already angiogenic and associated with
developing tumors.
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
inbred line of Cola1(I)r/+ mice, and a breeding colony of
homozygous mutant Cola1(I)r/r mice was established (UCSF).
Controls were the progeny of Cola1(I)+/+ breeding pairs that did
not possess the mutated gene but were on the same genetic
background. The presence of the mutant Col1a1 allele was assessed
by PCR genotyping of tail DNA using oligonucleotide primers that
discriminated between the wt allele (5-TGGACA -
ACGTGGTGTGGTC-3 and 5-TTGAACTCAGGAATT TAC -
CTGC-3) and the mutant allele (5-TGGACAACGTG -
GTGTGGTC-3 and 5-TGGACAACGTGGTGCCGCG-3) when
DNA was successively amplified for 30 cycles at 95°C for 60 seconds,
59°C for 30 seconds, and 72°C for 120 seconds. Mice carrying
targeted null mutations in the Mmp2, Mmp8, Mmp13 or Mmp14
genes (Itoh et al., 1997; Zhou et al., 2000; Balbin et al., 2003; Stickens
et al., 2004) were individually backcrossed into the FVB/n
background for five generations, before they were intercrossed, and
homozygous null genotypes were then generated and compared
with littermate controls. Gene-switch K14-GLp65/tata.TGFb1 mice
were generated and maintained as described previously (Cao et al.,
2002; Lu et al., 2004). Expression of the TGFb1 transgene (Tgfb1)
was induced in 4-week-old bigenic mice by topical application of
RU486 on ear skin, once a day for 3 days, at a dose of 20 mg/mouse
(dissolved in 50 ml of sesame oil); mice were then analyzed on day
4. K14-HPV16 and MMTV-PyMT mice were maintained in the
FVB/n strain and analyzed as described previously (Guy et al., 1992;
Coussens et al., 1996).
Neutralization of TGFb activity in vivo was accomplished by
intraperitoneal (i.p.) injections of pan-specific TGFb antibody (R&D
Systems, MN; #AB-100; 1.0 mg/ml in sterile PBS, pH 7.4), at 5.0
mg/kg body weight, at 120, 96 and 24 hours before MO challenge.
Control animals received normal rabbit IgG (R&D Systems;
#AB-105-C). Five animals per cohort were injected and the
experiment was repeated three times. GM6001 {N-[(2R)-2-
hydroxyamidocarbonylmethyl-0-4-methylpentanoyl]-L-tryptophan
ethylamide} (Galardy et al., 1994), a broad, class-specific MP inhibitor
(Chemicon International, CA), was administered i.p., at 100 mg/kg
body weight, as a 20 mg/ml slurry in 4.0% carboxymethylcellulose
(CMC) in 0.9% PBS, daily, for 3 days prior to cutaneous challenge.
Controls were treated with a daily injection of 4% CMC in PBS. Four
animals per cohort were injected and the experiment was repeated
four times. This concentration of GM6001 has been demonstrated
to inhibit in vivo MP activity (Zheng et al., 2000). Pharmacological
inhibition of ALK5 was achieved using the ALK5 kinase inhibitor
[3-(pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole (Calbiochem, San
Diego, CA), which was administered i.p., at 1.0 mg/kg, in 2% DMSO
in sterile PBS every other day for 6 days. Control mice received
equivalent i.p. injections of the solvent vehicle DMSO. For
biodistribution studies with dextran, mice were intravenously given
100 ml of lysine-fixable dextran 10,000 kDa Alexa Fluor 647 at 2.0
mg/ml (Molecular Probes) and 50 ml dextran 70,000 kDa
tetramethylrhodamine at 4.0 mg/ml (Molecular Probes), and were
studied 3 hours later. All analyses used age-matched mice and five
mice per treatment group, and all experiments were repeated a
minimum of three separate times. For all other experiments, analyses
were conducted in triplicate on cohorts containing at least three mice
and P values of <0.05 were considered significant. All animal
experiments were conducted in accordance with procedures
approved by the IACUC, UCSF.
Miles assay
Evans Blue (EB) dye (30 mg/kg in 100 ml PBS; Sigma-Aldrich, St
Louis, MO) was injected into the tail vein of 7- to 8-week-old mice
in all analyses, except for MMP14 null animals where, owing to
early neonatal lethality, 17-day-old mice were injected i.v. with EB
dye retro-orbitally, and assayed as described below. In some
experiments, after 1 minute, 30 ml of 5% MO (phenyl isothiocyanate,
98%, Sigma-Aldrich) diluted in MnO (Sigma-Aldrich) was applied
to the dorsal and ventral surfaces of the ear; the application process
was repeated 15 minutes later. Isoflurane-anesthetized mice were
photographed 30 minutes after the injection of EB dye.
Anesthetized mice were then cardiac-perfused (see below), their
ears removed, and blotted dry and weighed. EB dye was extracted
from ears in 1 ml of formamide, for 12-48 hours at 60°C, and
measured spectrophotometrically at 610 nm in a SpectraMax 340
(Molecular Devices, Sunnyvale, CA). Data are expressed as mean
± S.E.M. Comparisons of the amounts of dye extravasation were
evaluated by Mann-Whitney statistical test with P values less than
0.05 considered significant. In some experiments, 5 minutes prior
to the infusion of EB dye, shaved 5- to 7-week-old mice were
injected intradermally (10 ml) with one of the following agents at
the concentrations shown: VEGF120 (R&D Systems), VEGF164
(Chemicon International), histamine (Calbiochem) or serotonin
(Sigma-Aldrich). The appearance of a blue spot was monitored for
30 minutes, at which time mice were euthanized, cardiac-perfused,
photographed, and the area of skin surrounding the site of injection
was excised (~5 mm2), photographed, and the EB dye extracted as
above.
Vascular perfusions and fluorescent angiography
Isoflurane-anesthetized mice were injected with fluorescein-labeled
Lycopersicon esculentum lectin (100 ml, 2 mg/ml; Vector
Laboratories, Burlingame, CA) or rhodamine-labeled Ricinus
communis agglutinin I (50 ml, 5.0 mg/ml; Vector Laboratories) into
the femoral vein, as described (Thurston et al., 1996; Thurston et
al., 1998). Two minutes after lectin injection, mice were perfused
with fixative (1% paraformaldehyde plus 0.5% glutaraldehyde in
PBS, pH 7.4, at 37°C) through the ascending aorta for 2 minutes
to fix the vasculature and flush out non-adherent leucocytes.
Confocal images were acquired on a Zeiss LSM 510 META NLO
with an ultrafast, tunable Coherent Ti:Sa MIRA laser with Verdi
pump for multi-photon excitation.
Immunohistochemistry
Immunodetection of a-smooth muscle actin was performed on
tissue pieces following injection of Ricinus communis lectin and
cardiac perfusion, as described above. Tissue pieces were fixed in
4% paraformaldehyde for 4 hours in the dark at 4°C, with gentle
agitation, followed by several washes in 4°C PBS, before being
permeabilized in 0.3% Triton X-100 overnight with gentle agitation
at 4°C. Tissue pieces were then incubated with a Cy3-labeled anti-
a-smooth muscle actin monoclonal antibody (mAb) (Sigma-
Aldrich; Clone 1A4 #C6198, 1:500) diluted in 5% normal goat
serum, 2.5% BSA, 0.3% Triton X-100 in PBS, overnight at 4°C on
a rotating platform, followed by extensive washing in 4°C PBS and
mounting with Vectashield (Vector Laboratories) mounting
medium. Images were acquired on a Zeiss LSM 510 META NLO
with an ultrafast, tunable Coherent Ti:Sa MIRA laser with Verdi
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pump for multi-photon excitation. Immunodetection of TGFb in
ear skin was performed on formalin-fixed, 5-mm, paraffin-
embedded sections incubated with a mouse monoclonal anti-TGFb
antibody (R&D Systems; clone: 1D11) at a 1:50 dilution, revealed
with biotinylated goat anti-mouse secondary antibody, at a 1:200
dilution, and counterstained in 1.0% methyl green and mounted
with Cytoseal 60.
Immunofluorescence (IF) for aSMA and ALK5 was performed
on 10-mm cryo-frozen tissue sections of ear skin that were fixed for
10 minutes with cold acetone, blocked for 30 minutes, and incubated
with primary antibodies (ALK5, 1:50 dilution; Abcam #31013; aSMA
clone 1A4, 1:100 dilution; Sigma) overnight at 4°C, followed by
successive PBS washes and the application of secondary antibodies
(1:500). Following further PBS washes, the sections were mounted
with Vectashield media containing DAPI (Vector) and analyzed using
a confocal microscope LSM 510 with a 63 oil objective, and images
were then analyzed with a Zeiss LSM image examiner.
Immunodetection of MMP14 protein in collagen matrices was
performed after incubation of cells in three-dimensional (3D)
collagen gels for 18 hours without serum. The medium was then
aspirated from each well and the cells were immediately fixed with
2.0% paraformaldehyde (2% PFA in PBS, pH 7.4, freshly prepared)
for 20 minutes at room temperature (RT), then permeabilized with
PBS containing 0.5% Triton X-100 for 10 minutes at 4 C, washed
three times with PBS-glycine (130 mM NaCl, 7.0 mM Na2HPO4, 3.5
mM NaH2PO4, 10 mM glycine), and then blocked with 200 ml/well
of IF buffer (130 mM NaCl, 7.0 mM Na2HPO4, 3.5 mM NaH2PO4,
0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20) with 10% goat serum
for 1 hour at RT. The primary rabbit polyclonal anti-MT1-MMP
(hinge region) antibody (AB815, Chemicon), which was diluted at
1:250 in IF Buffer with 10% goat serum, was incubated overnight at
4°C. Samples were washed three times with IF buffer for 20 minutes
each, followed by incubation with Alexa Fluor 488 goat anti-rabbit
antibody, diluted 1:200 in IF buffer with 10% goat serum, for 45
minutes. Cells were then washed three times with IF buffer, cover
slipped with the gel, and mounted in Vectashield with DAPI
mounting medium, and allowed to air dry. Once dry, slides were
observed by laser confocal microscopy using a Zeiss LSM META.
Protein analysis
VEGFR2
Tissue pieces (5 mm2) were collected from ears, or shaved back skin,
following the injection (i.d.) of 10 ml of 10 ng VEGF164 or 0.1% BSA
in PBS. Tissues were pulverized in liquid nitrogen (N2), followed by
lysis in ice-cold buffer containing 20 mM Tris, pH 7.6, 150 mM NaCl,
1.0 mM EDTA, 50 mM NaF, 1.0% Triton X-100, 0.5% Na-
deoxycholate, 0.1% SDS, 2.0 mM Na2VO4, 10 mg/ml aprotinin and
1.0 mM phenylmethylsulfonylfluoride, and centrifuged at 10,000 rpm
(9503  g) for 30 minutes at 4°C. The supernatants were re-
centrifuged at 10,000 rpm for 30 minutes at 4°C. Lysates were then
incubated in a slurry of heparin-sepharose CL-6B (Pharmacia,
Peapack, NJ) and incubated overnight, rocking at 4°C, and then
centrifuged and equilibrated to 150 mM NaCl. Protein was dialyzed
against PBS and quantified using the Bio-Rad protein assay system
(Bio-Rad, Hercules, CA). Before immunoprecipitation, BSA was
added to the pre-cleared lysates at 0.5%. Equal amounts of protein
(1.0 mg) from lysates were used for immunoprecipitations and
western blotting. Incubation of tissue lysate with goat anti-Flk-1
(Santa Cruz Biotechnology, Santa Cruz, CA) followed by protein-G
sepharose beads was performed for 2 hours at 4°C.
Immunoprecipitates were washed three times with 20 mM Tris (pH
7.6), 150 mM NaCl and 0.1% Triton X-100, and bound proteins were
eluted by boiling in 1 SDS-PAGE sample buffer for 5 minutes,
followed by electrophoresis on 10% SDS-PAGE under reducing
conditions. The resolved proteins were transferred to a nitrocellulose
membrane (BA-S85; Schleicher & Schuell BioScience, Inc., Keene,
NH). Anti-phosphotyrosine PY-20 (Upstate Biotechnology, Lake
Placid, NY) and anti-Flk-1 (Santa Cruz Biotechnology) antibodies
were used on western blots. Immunodetection was performed by
incubation with specific peroxidase-conjugated secondary antibodies
followed by enhanced chemiluminescence (ECL) (Amersham
Biosciences, Piscataway, NJ).
TGFb ELISA
Tissues were pulverized in liquid N2 and solubilized in lysis buffer
containing 50 mM Tris, 75 mM NaCl, 10 mM EDTA, protease
inhibitor cocktail mix without EDTA (Roche, Indianapolis, IN), 0.01
mg/ml aprotinin (Sigma-Aldrich), 0.1 mg/ml leupeptin (Sigma-
Aldrich) and 10 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-
Aldrich) using a 2.0 ml tissue grinder (Fisher Scientific, Pittsburgh,
PA), followed by centrifugation at 10,000  g for 30 minutes at 4°C.
Protein concentration was determined using the Bio-Rad DC Protein
assay reagent according to the manufacturer’s instructions (Bio-Rad).
To determine total levels of TGFb1 in tissue lysates, a standard
protocol for quantitative sandwich enzyme immunoassay was used.
For ELISA analysis, a monoclonal antibody specific for active TGFb1,
b2 and b3 (1.0 mg/ml in PBS; R&D Systems; MAB1835) was used to
pre-coat maxisorb immunoplates (Nalge Nunc International,
Rochester, NY) overnight at RT. Lysates (100 mg) were activated by
adding 1.0 N HCl (1:25) and incubated for 1 hour at 4°C with gentle
agitation. Acidified samples were neutralized by adding 1.0 N NaOH
(1:25) and diluted with ELISA sample buffer (1 PBS, 0.05% Tween-
20, 1.4% fatty acid-free BSA). Samples were then added to pre-coated
maxisorb immunoplates and incubated for 3 hours at RT, which was
followed by the addition of biotinylated anti-TGFb1 antibody (200
ng/ml; R&D Systems; BAF240) and incubation overnight at 4°C.
Avidin-peroxidase conjugate (1:1000; Sigma-Aldrich) was added for
1 hour at RT followed by a 20-minute incubation with o-
phenylenediamine (OPD) substrate at RT in the dark (Sigma-
Aldrich). The reaction was stopped by addition of 1.0 M H2SO4 and
absorbance was measured at 450 nm (570 nm for background
corrections) on a Molecular Device Spectra Max 340. Recombinant
human TGFb1 (R&D Systems) was used as a standard control. Six
tissues samples per genotype were analyzed and all samples were
analyzed in duplicate.
TGFb and LAP
For immunoprecipitation of TGFb, 4.2 mg of protein lysates were
pre-cleared with protein A-agarose beads (Roche) for 1 hour at 4°C,
followed by centrifugation at 3000 rpm (5 minutes). The
supernatant was then incubated with 2.0 mg of antibody for TGFb1,
b2 and b3 (R&D Systems; MAB1835) or MMP14 (Chemicon
International; AB8102, catalytic domain; MAB3317, hemopexin
domain) for 3 hours at 4°C in HNTG buffer (20 mM HEPES, pH
7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerin, 10 mM Na
pyrophosphate, 10 mM NaF, 1 mM Na-o-vanadate, 1 mM PMSF
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and 10 mg/ml aprotinin). After incubation with protein agarose G
or A beads (Roche) for an additional hour at 4°C, the lysates bound
to agarose beads were washed three times with HNTG buffer, and
bound proteins were eluted by boiling in 1 reduced SDS-PAGE
sample buffer for 5 minutes and then centrifuged at 13,000 rpm
for 10 minutes. Tissue lysates (20 mg for LAP) or eluted
immunoprecipitated complexes were separated by electrophoresis
on 10% SDS polyacrylamide gels, and transferred to nitrocellulose
membranes overnight at 4°C. Membranes were blocked, incubated
with primary antibodies for 1-2 hours at RT, washed, and then
incubated with secondary antibodies (Bio-Rad; goat anti-rabbit- or
goat anti-mouse-HRP conjugate 1:2000) or strepavidin-HRP
conjugate (Sigma-Aldrich; 1:20,000) for 1 hour at RT. Membranes
were then washed and developed by using an ECL kit (Amersham
Biosciences). Biotinylated LAP antibodies (R&D Systems; BAF246,
1:1000), biotinylated anti-TGFb1 antibodies (R&D Systems;
BAF240, 1:1000) and antibodies to MMP14 (Oncogene Science,
Cambridge, MA, 1M397, 1:1000; Chemicon International, AB8104,
1:1000) were used for detection on membranes. For the loading
control in LAP western analysis, a rat monoclonal antibody
(AbCam, Cambridge, MA; YL1/2, 1:5000) against a-tubulin and a
goat anti-rat-HRP (Pierce, Rockford, IL; 1:2000) were used.
TGFb bioassay
TGFb bioavailabilty in tissue lysates from mice, and in conditioned
medium from MDA-MB-MMP14 cells grown in either +/+ or r/r
collagen matrices, was assayed using mink lung epithelial cells
(MLEC) transfected with a luciferase reporter gene under the control
of the TGFb-sensitive promoter (PAI-1), and maintained as described
previously (Abe et al., 1994). PAI-1-MLEC cells (2.5104) were
cultured in 96-well culture plates in 500 ml DMEM containing 10%
FBS, and allowed to attach for 6 hours at 37°C. After two PBS washes,
the medium was replaced with tissue lysate or conditioned medium.
Tissue lysates were prepared as described above for ELISA. 50 mg of
total proteins was diluted in incubation medium [high-glucose
DMEM, 0.2% BSA (Fraction V, fatty acid-free; Calbiochem),
penicillin/streptomycin, 2.0 mM L-glutamine, 250 mg/ml G-418
sulfate] and incubated with PAI-1-MLEC cells for 20 hours in the
presence or absence of anti-TGFb antibody (15 mg/ml; R&D Systems;
clone 1D11). For conditioned medium analyses, MDA-MB-231 cells
were grown in either +/+ or r/r collagen, as described above, and
incubated in the presence or absence of GM6001 (10 mM; Chemicon
International) or anti-TGFb antibody (15 mg/ml). Conditioned
medium (50 ml) was diluted in 50 ml of incubation medium and
incubated with PAI-1-MLEC cells for 20 hours. Cells were washed
twice with PBS, incubated with lysis buffer (Promega, Madison, WI),
and luciferase activity was then measured using a Luciferase Assay
System kit (Promega) following the manufacturer’s instructions.
Relative luminescence units (RLU) were calculated as an average from
triplicate wells per culture condition and repeated in triplicate.
RNA analysis
Total RNA was extracted from shaved back skin or ear pieces with
TRIzol reagent (Invitrogen, New York, NY), according to the
manufacturer’s recommendations, by powdering fresh-frozen tissue
samples in liquid N2, homogenizing with a microtube pestle (USA
Scientific, Ocala, FL), shearing by multiple passages through a
syringe and 21-gauge needle (Becton Dickinson, Franklin Lakes, NJ),
followed by chloroform extraction, isopropanol precipitation, and
an ethanol wash. Northern blot analysis was performed using
standard methods with 10 mg of total cellular RNA. Probes were
generated by random primed labeling of DNA isolated from plasmids
using standard methodology (Maniatis et al., 1982). Northern blots
were hybridized at 65°C overnight in Church buffer (0.5 M sodium
phosphate, pH 7.2, 1.0 mM EDTA, 7.0% w/vol SDS, 250 mg/ml tRNA),
and subsequently washed at 62°C in 2 SSC containing 1.0% SDS.
The probes used for hybridization were: a 335 bp fragment of Mmp2
(EMBL: M84324; position: 2053-2387 bp), a 335 bp fragment of
Mmp14 (EMBL: NM_008608; position: 54-388 bp), a 669 bp
fragment of Timp2 (EMBL: X62622; position: 2-670 bp), a 974 bp
fragment of Tgfb1 (EMBL: M13177; position: 421-1395 bp) and a
207 bp fragment for 18S RNA as a loading control (EMBL: J00623;
position: 13-219 bp). Hybridized filters were exposed overnight on
phosphor screens, analyzed in a Phosphoimager (Molecular
Dynamics, Sunnyvale, CA; Storm 860, ImageQuant 5.2 software),
and then additionally exposed for 1-3 days on Kodak Biomax MS
films (Kodak, Rochester, NY) with an intensifier screen at –80°C.
Substrate conversion assay
Shaved dorsal skin pieces isolated from 5–8-week-old mice were
pulverized in liquid N2 and solubilized in 500 ml buffer [0.25 M
sucrose, 5 mM Tris, pH 7.5, protease inhibitor cocktail mix without
EDTA (Roche), 0.25 mg/ml Pefablock (Roche), 0.01 mg/ml
aprotinin (Sigma-Aldrich)] and centrifuged at 800  g for 15
minutes at 4°C. Supernatants were then centrifuged for 1 hour at
100,000  g at 4°C, and pellets were resuspended in 100 ml
solubilization buffer and homogenized by sonication at 4°C. Protein
concentration was determined using the Bio-Rad DC Protein assay
reagent according to the manufacturer’s instructions (Bio-Rad).
Lysate buffers were then exchanged with 10 mM Tris, pH 7.5, using
Micro Bio-Spin chromatography columns (Bio-gelP-6; Bio-Rad). To
determine gelatinolytic activity in tissue lysates, supernatant
fractions (50 mg) were incubated with 400 ng DQ-gelatin (Molecular
Probes) in reaction buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 5.0
mM CaCl2, 0.2 mM sodium azide and 0.05% BrJ35) at 37°C.
Reactions were analyzed for 5 hours at 37°C and fluorescence
measured (excitation 485 nm, emission 530 nm) every 3 minutes
using a microplate spectrofluorometer (SpectraMax Gemini EM,
Molecular Devices) operated by SoftMax Pro 4.1 software. Values
shown represent the mean ± S.E.M. from three tissue pieces and
are representative of analyses performed in triplicate. Each
experiment was repeated three independent times.
Substrate zymography
Tissue samples (ear) from 5–8-week-old mice were weighed and
homogenized (1:8 weight to volume) in lysis buffer containing 50
mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% NP-40, 0.5%
deoxycholate and 0.1% SDS. Soluble and insoluble extracts were
separated by centrifugation (10,000  g) and subsequently stored
at –80°C. Equivalent amounts of soluble extract were analyzed by
gelatin zymography (Herron et al., 1986a) on 10% SDS-
polyacrylamide gels co-polymerized with substrate (1.0 mg/ml of
gelatin) in sample buffer (2% SDS, 50 mM Tris-HCl, 10% glycerol,
0.1% Bromophenol Blue, pH 6.8). After electrophoresis, gels were
washed three times for 30 minutes in 2.5% Triton X-100, then
washed three times for 15 minutes in ddH2O, incubated overnight
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at 37°C in 50 mM Tris-HCl and 10 mM CaCl2 (pH 8.2), and then
stained in 0.5% Coomassie Blue and destained in 20% methanol,
10% acetic acid. Negative staining indicates the location of active
protease bands. Exposure of pro-enzymes within tissue extracts to
SDS during the gel separation procedure leads to activation without
proteolytic cleavage (Herron et al., 1986b).
Cell-based MMP assay
To prepare collagen gels for culture experimentation, mouse tail
collagen was purified as described previously (Miller and Rhodes,
1982) and quantified by determination of hydroxyproline content
(Woessner, 1961; Bergman and Loxley, 1963). Subsequently, eight
volumes of +/+ and r/r collagen (4.4 mg/ml) were neutralized by
the addition of one volume of 10 PBS containing 0.005% Phenol
Red and one volume of NaOH. 50 ml of MDA-MB-231 breast
carcinoma cells expressing a full-length human MMP14 cDNA
(Tam et al., 2004), at 5106 cells/ml in serum-free DMEM, were
added to 200 ml of neutralized +/+ and r/r collagen. The
collagen/cell suspensions were mixed thoroughly and then four 50
ml aliquots were added per well into a 96-well culture dish (Corning,
Corning, NY) and incubated at 37°C for 1 hour to allow collagen
polymerization. 100 ml of DMEM containing 10% fetal bovine
serum was then added to cells and incubated at 37°C for 18 hours.
Collagen gels were washed with 200 ml serum-free DMEM, and
cells were then incubated in 100 ml serum-free DMEM containing
human proMMP2, since the MDA-MB-231 cells essentially express
no MMP2. Conditioned medium was harvested after 48 hours and
collagen gels were washed in 200 ml of PBS. 50 ml of non-reducing
SDS-PAGE sample buffer was then added to collagen gels to extract
the collagen-bound MMP2 and then, after collection, the sample
buffer was used to bring the total volume to 200 ml. Equivalent
amounts of supernatants and collagen-bound MMP2 extracts were
analyzed by gelatin zymography and incubated for 4 hours at 37°C.
In vivo measurements of vascular leakage
MMTV-PyMT mice (Guy et al., 1992) (approximately 100 days old)
were treated with the ALK5 inhibitor [3-(Pyridin-2-yl)-4-(4-
quinonyl)]-1H-pyrazole (Calbiochem), which was given i.p. every
other day at 1.0 mg/kg in 2% DMSO in sterile PBS. Control mice
received vehicle alone. On day 6 of treatment, tumors were imaged
in live mice as described previously (Egeblad et al., 2008). Briefly,
the mice were anesthetized and the inguinal mammary gland
containing a tumor was surgically exposed. Images from live mice
were acquired using a Fluor 10/0.5 NA lens and a micro-lensed
spinning disk confocal microscope (Solamere Technology Group,
Salt Lake City, UT) equipped with argon and krypton lasers
(Dynamic Lasers, Salt Lake City, UT). Images were collected with
an ICCD camera (XR-Mega-10EX S-30, Stanford Photonics, Palo
Alto, CA). The anesthetized mice were injected i.v., into the tail
vein, with 100 ml sterile PBS containing 1.0 mg/ml 10 kDa Alexa
Fluor 647-conjugated dextran, 2.0 mg/ml 70 kDa rhodamine-
conjugated dextran and 0.4 mM Qtracker 705 non-targeted
quantum dots (all from Invitrogen). Five animals in each group were
imaged and the tumors were between 6-11 mm in diameter.
From the acquired image sets, maximum intensity projections
of 16-mm optical sections were generated using Bitplane Imaris
(version 5.7 for Windows X64). To determine dextran leakage, these
sets were analyzed further using Improvision Volocity (version 4.1.0
for Windows). Pixel intensities in the quantum dot channel that
were below 125% of the mean background intensity were used to
define the extravascular space (negative for quantum dots). Leakage
of 10 kDa or 70 kDa dextran to the extravascular space was defined
as the percentage of the extravascular space with pixel intensities
above 150% of the mean background intensity levels. From each
mouse, 3-5 fields of view (imaged in parallel) were analyzed. The
average percentage of extravascular leakage for the five mice in each
group is reported. Differences in dextran leakage between controls
and ALK5 inhibitor-treated mice were compared using Student’s
t-test (two-tailed, unequal variance) using GraphPad Prism 4
software.
Statistical analysis
Statistical analyses were performed using GraphPad Prism and/or
InStat software. The specific tests used were Student’s t-test,
Mann-Whitney (unpaired, nonparametric, two-tailed) test, and
unpaired t-test with Welch’s correction. P values <0.05 were
considered statistically significant.
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TRANSLATIONAL IMPACT
Clinical issue
In patients with locally advanced solid tumors, the first-line treatment is often
neo-adjuvant or pre-operative chemotherapy, which helps shrink tumors
before surgery, allowing for more conservative surgical approaches and
reducing the potential for developing systemic disease. However, despite
aggressive chemotherapy, long-term survival for many patients remains poor,
in part owing to limitations with the targeting and accumulation of cytotoxic
drugs in tumor tissue.
The vasculature of solid tumors is abnormal, both in terms of vessel
architecture and the dynamics of blood flow. Permeable heterogeneous vessel
walls allow the leakage of proteins and fluid that, coupled with the inefficiency
of lymphatic drainage, could be exploited to develop novel, enhanced drug
delivery strategies that are therapeutically selective and improve clinical
outcome.
Results
This work describes a previously unappreciated role for transforming growth
factor beta (TGFb) in regulating vascular stability and vessel permeability in
solid tumors. Using mouse models, the authors demonstrate an endogenous
pathway that regulates normal vascular permeability, which is controlled by
perivascular collagen, the metalloproteinase enzyme MMP14, and TGFb. In
wild-type mice, inhibitors of either MMP14 or TGFb signaling induce blood
vessel permeability. Conversely, enhanced MMP14 or TGFb activity in the
mouse epidermis decreases leakage across cutaneous vessels. This pathway
remains functional during tumor progression, as acute blockade of either
MMP14 or TGFb signaling transiently alters vessel stability, ‘opening’ vascular
beds and promoting intravenous delivery of high molecular weight
compounds to the tumor.
Implications and future directions
The delivery of standard therapeutic agents or diagnostic molecular imaging
agents to tumor tissue may be enhanced by transient blockade of the TGFb
pathway. If so, this could advance disease therapy and/or diagnostic imaging,
not only in cancer medicine, but also in fibrotic disorders such as scleroderma
and kidney failure.
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